ClinicalTrials.gg
CompletedNCT00319449Updated Feb 9, 2022Results posted

Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)

A Phase 4 interventional study of Ezetimibe and Placebo in Hypercholesterolemia and Coronary Arteriosclerosis, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
90th of 97
22 · median 148
Started
2005
with 13 others
Phase 4
31 of 98
1 open now
Registered
16th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 90th largest by enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2005, is one of 31 in phase 4, and was the 16th registered.

Hypercholesterolemia

1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe 10 mg coadministered with atorvastatin 10 mg versus atorvastatin 10 mg in Indonesian population with primary hypercholesterolemia.

03

Conditions studied

  • Hypercholesterolemia
  • Coronary Arteriosclerosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have an LDL-C concentration >= 3.3 mmol/L (130 mg/dL) to \<= 4.9 mmol/L (190 mg/dL) using the Freidewald calculation.
  • Participants must have triglyceride concentrations of \< 3.99 mmol/L (350 mg/dL).
  • Participants must have two or more coronary heart disease risk factors listed below:

    • Current cigarette smoking
    • Hypertension (BP >= 140/90 mmHg or on antihypertensive medication)
    • Low HDL cholesterol (\< 40 mg/dL)
    • Family history of premature CHD (CHD in male first degree relative \< 55 years; CHD in female first degree relative \< 65 years)
    • Age (Men >= 45 years; women >= 55 years)
  • Participant must be currently taking atorvastatin 10 mg daily and by history has taken 80% of daily doses for the 6 weeks prior to participating.
  • Participants must have liver transaminases (, AST) \< 50% above the , with no active liver disease, and CK \< 50% above the upper limit of normal.
  • Participants must have maintained a cholesterol lowering diet, exercise program, and stable weight for at least 4 weeks prior to the study and be willing to continue the same diet and exercise program during the study.
  • Women receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral , must have been maintained on a stable dose and regimen for at least 8 weeks and be willing to continue the same regimen for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Participants who meet any of the following criteria will be excluded:
  • (BMI = weight [kg]/height**2[m]) is >= 30 Kg/m**2.
  • Consume > 14 alcoholic drinks per week.
  • Women who are pregnant or nursing.
  • Congestive heart failure defined by as Class III or IV.
  • Uncontrolled cardiac arrhythmia.
  • Coronary heart disease (CHD).
  • Unstable or severe peripheral artery disease within 3 months of participating
  • Uncontrolled hypertension (treated or untreated) with systolic blood pressure > 160 mm Hg or diastolic > 100 mm Hg.
  • Type I or Type II diabetes mellitus.
  • Secondary causes of hyperlipidemia, such as secondary hypercholesterolemia due to hypothyroidism.
  • Impaired renal function (creatinine > 2.0 mg/dL) or nephrotic syndrome.
  • Known positive.
  • Cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas).
  • History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.
  • Participants who are on any of the following concomitant medications:
  • Participants who are on medications that are potent inhibitors of , including cyclosporine, systemic itraconazole, fluconazole, and ketoconazole, erythromycin or clarithromycin, nefazodone, mibefradil, protease inhibitors and large amounts of grapefruit juice (> 1 quart/day).
  • Participants who are on lipid-lowering agents (other atorvastatin): niacin (> 200 mg/day)
  • Participants who are on over the counter lipid lowering agents such as fish oils, garlic and cholestin
  • Participants who are on oral , unless used as replacement therapy for pituitary/adrenal disease and the subject is on a stable regimen for at least 6 weeks.
  • Participants who are currently using psyllium, other fiber-based laxatives, and/or any other OTC therapy known to affect serum lipid levels (phytosterol margarine), and have not been on a stable regimen for at least 5 weeks and who do not agree to remain on this regimen throughout the study.
  • Participant who are currently using orlistat or sibutramine.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Ezetimibe 10 mg

    Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.

    Drug: Ezetimibe · Drug: Atorvastatin 10 mg

  • Placebo comparator
    Placebo 10 mg

    Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.

    Drug: Placebo · Drug: Atorvastatin 10 mg

Interventions

  • 10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin

  • DrugPlacebo

    10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin

  • 10 mg/day atorvastatin, orally, (ongoing treatment in participants)

06

What researchers measure

Primary outcomes

  1. Low Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg

    12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - \[HDL-C + TG/5\]) before and after treatment.

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. Number of Participants Who Achieve the Target LDL-C Concentration of < 3.3 mmol/L (130 mg/dL)

    12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - \[HDL-C + TG/5\] after treatment for 6 weeks.

    Time frame: 6 weeks post treatment

  2. High Density Lipoprotein-cholesterol (HDL-C), Total Cholesterol and Triglycerides at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg

    12-hour fasting blood samples were collected in participants and the high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol was measured with the basic lipid panel test.

    Time frame: 6 weeks post treatment

07

Results

Posted May 10, 2011
Limitations and caveats
Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.

Participant flow

Participant flow — Overall Study
MilestoneEzetimibe 10 mgPlacebo 10 mg
Started1012
Completed812
Not completed20
Withdrew: Subject did not wish to continue10
Withdrew: Noncompliance with the protocol10

Outcome measures

PrimaryLow Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg

12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - \[HDL-C + TG/5\]) before and after treatment.

Time frame:
Baseline and 6 weeks
Reported as:
Mean · mg/dL
Low Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg
mg/dLEzetimibe 10 mgPlacebo 10 mg
Baseline148.125 (130.126 to 166.124)151.083 (136.387 to 165.780)
6 weeks post treatment106.000 (89.030 to 122.970)108.273 (92.923 to 123.622)
SecondaryNumber of Participants Who Achieve the Target LDL-C Concentration of < 3.3 mmol/L (130 mg/dL)

12-hour fasting blood samples were collected in participants to measure high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol. LDL-C was measured using Friedewald calculation (LDL-C = Total C - \[HDL-C + TG/5\] after treatment for 6 weeks.

Time frame:
6 weeks post treatment
Reported as:
Number · Participants
Number of Participants Who Achieve the Target LDL-C Concentration of < 3.3 mmol/L (130 mg/dL)
ParticipantsEzetimibe 10 mgPlacebo 10 mg
Number of Participants Who Achieve the Target LDL-C Concentration of < 3.3 mmol/L (130 mg/dL)78
SecondaryHigh Density Lipoprotein-cholesterol (HDL-C), Total Cholesterol and Triglycerides at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg

12-hour fasting blood samples were collected in participants and the high density lipoprotein-cholesterol (HDL-C), triglycerides and total cholesterol was measured with the basic lipid panel test.

Time frame:
6 weeks post treatment
Reported as:
Mean · mg/dL
High Density Lipoprotein-cholesterol (HDL-C), Total Cholesterol and Triglycerides at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg
mg/dLEzetimibe 10 mgPlacebo 10 mg
HDL-C at baseline53.250 (44.579 to 61.921)57.667 (50.586 to 67.747)
HDL-C at 6 weeks52.625 (43.954 to 61.296)53.500 (46.420 to 60.580)
Total Cholesterol at baseline219.125 (202.355 to 235.895)226.000 (212.307 to 239.693)
Total Cholesterol at 6 weeks156.375 (139.605 to 173.145)185.667 (171.974 to 199.359)
Triglycerides at baseline139.500 (105.213 to 173.787)131.667 (103.672 to 159.662)
Triglycerides at 6 weeks115.250 (80.963 to 149.537)120.250 (92.255 to 148.245)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe 10 mg—1/10 (10%)2/10 (20%)
Placebo 10 mg—0/12 (0%)3/12 (25%)
Most frequent serious events
Most frequent serious events
EventEzetimibe 10 mgPlacebo 10 mg
Cardiac failure congestiveCardiac disorders1/100/12
Most frequent other events
Most frequent other events
EventEzetimibe 10 mgPlacebo 10 mg
NauseaGastrointestinal disorders1/100/12
ArthralgiaMusculoskeletal and connective tissue disorders1/100/12
MyalgiaMusculoskeletal and connective tissue disorders1/100/12
HeadacheNervous system disorders1/100/12
pruritisSkin and subcutaneous tissue disorders1/100/12
Decreased AppetiteMetabolism and nutrition disorders0/101/12
Back painMusculoskeletal and connective tissue disorders0/101/12
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders0/101/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ezetimibe 10 mgPlacebo 10 mgTotal
Mean57.4 ± 12.152.2 ± 10.454.5 ± 11.3
Age, Customized
Age, Customized(Participants)Ezetimibe 10 mgPlacebo 10 mgTotal
18 to <65 years71118
65 or older314
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe 10 mgPlacebo 10 mgTotal
Female358
Male7714
Region of Enrollment
Region of Enrollment(participants)Ezetimibe 10 mgPlacebo 10 mgTotal
Indonesia101222
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2006
First posted
Apr 27, 2006
Start
Sep 2005
Primary completionActual
Oct 2006
CompletionActual
Oct 2006
Results first posted
May 10, 2011
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00319449
Lead sponsor
Organon and Co
Collaborators
PT. Schering-Plough. Tbk Indonesia
Responsible party
Sponsor
First posted
Apr 27, 2006
Start date
Sep 2005
Primary completion
Oct 2006
Completion
Oct 2006
Results posted
May 10, 2011
Last update
Feb 9, 2022
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion